Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
May 22, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
May 12, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in...
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
March 30, 2023 07:00 ET
|
Centessa Pharmaceuticals plc
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
March 27, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
March 01, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
February 06, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
February 02, 2023 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
January 26, 2023 09:08 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
December 10, 2022 15:30 ET
|
Centessa Pharmaceuticals plc
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93%...
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
November 30, 2022 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are...